BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26147192)

  • 1. Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia.
    Wang HY; McMahon C; Ali SM; Young LE; Yekezare S; Ross JS; Ball ED
    Br J Haematol; 2016 Mar; 172(6):987-90. PubMed ID: 26147192
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
    Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
    Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
    Hinai AA; Valk PJ
    Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.
    Matsuo H; Goyama S; Kamikubo Y; Adachi S
    Haematologica; 2015 Mar; 100(3):e116-7. PubMed ID: 25740107
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia.
    Gaur GC; Ramadan SM; Cicconi L; Noguera NI; Luna I; Such E; Lavorgna S; Di Giandomenico J; Sanz MA; Lo-Coco F
    Ann Hematol; 2012 Dec; 91(12):1855-60. PubMed ID: 22895555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked thrombocytosis and dysmegakaryopoiesis in acute myeloid leukemia with t(2;3)(p22;q26.2) and EVI1 rearrangement.
    Yamamoto K; Okamura A; Sanada Y; Yakushijin K; Matsuoka H; Minami H
    Ann Hematol; 2013 Dec; 92(12):1713-5. PubMed ID: 23604431
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
    Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
    Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
    Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
    Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of sequences telomeric of the EVI1 gene in 3q26 associated with a novel pericentric inv(3)(p25q26) in a patient with acute myelogenous leukemia.
    Wieser R; Lechner K; Valent P; Fonatsch C
    Haematologica; 2003 Dec; 88(12):1427-9. PubMed ID: 14688000
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute myeloid leukemia with t(3;8)(q26;q24) complicated by diabetes insipidus.
    Kubota Y; Ichinohe T; Yoshimura M; Itamura H; Hisatomi T; Fukushima N; Sueoka E; Kimura S
    Ann Hematol; 2016 Mar; 95(4):653-5. PubMed ID: 26754632
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia.
    Chen H; Wang H
    Blood; 2024 Jan; 143(3):290. PubMed ID: 38236609
    [No Abstract]   [Full Text] [Related]  

  • 12. [Individualized treatment of leukemia patients by monitoring of minimal residual disease (MRD) based on WT1 assay].
    Ogawa H; Sugiyama H
    Rinsho Ketsueki; 1998 Feb; 39(2):107-8. PubMed ID: 9545812
    [No Abstract]   [Full Text] [Related]  

  • 13. The significance of detecting WT1 expression in childhood acute leukemias.
    Hu SY; Gu WY; Chen ZX; Wang XL; Cen JN; He HL; Chai YH; Chen CS
    Pediatr Hematol Oncol; 2010 Nov; 27(8):581-91. PubMed ID: 20863155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant Wilms' tumor 1 (WT1) mRNA with premature termination codons in acute myeloid leukemia (AML) is sensitive to nonsense-mediated RNA decay (NMD).
    Abbas S; Erpelinck-Verschueren CA; Goudswaard CS; Löwenberg B; Valk PJ
    Leukemia; 2010 Mar; 24(3):660-3. PubMed ID: 20016532
    [No Abstract]   [Full Text] [Related]  

  • 15. [Expression of Wilms' tumor gene (WT1) in leukemias and its clinical implication].
    Wu X; Wang Y; Pei X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):16-9. PubMed ID: 10921096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancer and fusion gene].
    Nakata M; Ohki M
    Tanpakushitsu Kakusan Koso; 1997 Sep; 42(12):1978-90. PubMed ID: 9301327
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia.
    Ishikawa Y; Kiyoi H; Naoe T
    Leuk Res; 2011 May; 35(5):685-8. PubMed ID: 21256590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines.
    Algar EM; Khromykh T; Smith SI; Blackburn DM; Bryson GJ; Smith PJ
    Oncogene; 1996 Mar; 12(5):1005-14. PubMed ID: 8649791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein.
    Takahashi S; Licht JD
    Leukemia; 2002 Sep; 16(9):1755-62. PubMed ID: 12200691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
    Hewitt SM; Hamada S; McDonnell TJ; Rauscher FJ; Saunders GF
    Cancer Res; 1995 Nov; 55(22):5386-9. PubMed ID: 7585606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.